Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's New in Anti-Androgens
Description
Dr. Maria Abri Martinez Velasco presented on the latest developments in anti-androgens, highlighting the need for new treatment options due to issues like the systemic reduction of libido and erectile dysfunction associated with current therapies like finasteride. She introduced a new finasteride patch that enhances transdermal absorption, potentially improving patient adherence. The findings from studies on finasteride and dutasteride regarding hair growth were discussed, revealing no significant changes in hair patterns with their use. Other promising compounds mentioned include duodextribose, which mimics BGF stimulation, and pyrilutamide, an androgen receptor antagonist with a phase three trial ongoing. Clascoterone was described as an androgen receptor inhibitor showing effective concentrations in previous studies but raised concerns about systemic effects. A topical androgen receptor degrader is in phase three trials, and a monoclonal antibody targeting a specific receptor pathway is also under investigation. Further, a meta-analysis indicated no increased suicide risk associated with finasteride or dutasteride, reinforcing their safety. Dr. Martinez emphasized the importance of endocrinological evaluations for adolescents with androgenetic alopecia before initiating treatment and suggested various treatment alternatives for different patient demographics, including minoxidil, spironolactone, and careful use of inhibitors based on individual patient health profiles.
View moreConclusions
- Research highlights the need for new options in treating androgenetic alopecia due to side effects associated with existing treatments like finasteride.
- A new finasteride patch offers benefits of transdermal administration, reducing side effects and improving treatment adherence.
- Studies suggest that finasteride and dutasteride do not significantly affect beard growth patterns.
- The sugar compound 2-deoxy-D-ribose shows potential in promoting neovascularization and hair growth, similar to minoxidil.
- Pyrilutamide, as an androgen receptor antagonist, demonstrates efficacy in hair regrowth and is already available in some markets, showing effective concentrations in trials.
- Clascoterone, a selective androgen receptor inhibitor, has shown significant promise for hair loss treatment in various concentrations with fewer side effects.
- The topical androgen receptor degrader GT-20029 could provide a safer method of treatment by avoiding systemic exposure while effectively degrading androgen receptors.
- Clinical findings indicate no increased cancer risk from 5-alpha reductase inhibitors in women, challenging previous concerns related to hormonal treatments.
- There is no significant association between the use of 5-alpha reductase inhibitors and suicidal risk or depression, suggesting their safety in this regard.
- Int J Pharm. 2024 Dec 5:666:124802. doi: 10.1016/j.ijpharm.2024.124802. Epub 2024 Oct 4.
- Actas Dermosifiliogr. 2024 Nov-Dec;115(10):1015-1016. doi: 10.1016/j.ad.2023.05.046. Epub 2024 Jul 20.
- Ellis JA, Sinclair R, Harrap SB. Expert Rev Mol Med. 2022; 4(22): 1-11. https://www.ncbi.nlm.nih.gov/pubmed/14585162
- Saceda -Corralo D, Dominguez-Santas M, Vaño-Galvan. Whats new in therapy for male androgenetic Alopecia. Am J Clin Dermatol 2023 Jan ;24(1):15-24.
- J Am Acad Dermatol. 2025 Feb;92(2):343-345. doi: 10.1016/j.jaad.2024.10.023. Epub 2024 Oct 21.
- J Am Acad Dermatol. 2025 Jan;92(1):163-165. doi: 10.1016/j.jaad.2024.09.028.
- Eur Urol Focus. 2024 Sep;10(5):751-753. doi: 10.1016/j.euf.2024.04.009.
- Actas Dermosifiliogr. 2024 Apr;115(4):347-355. doi: 10.1016/j.ad.2023.10.013. Epub 2023 Oct 27.